{"schema_version":"secwatch.filing_event.v1","accession":"0000950123-21-010438","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.915583+00:00","generated_at":"2026-06-29T13:54:07.760651+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monte Rosa Q2 net loss $18.4M; $255.6M IPO extends cash into late 2024","bullets":["R&D expenses $14.6M (Q2 2020: $4.9M), G&A $3.5M ($0.5M) as headcount and lab activities expanded.","Cash and equivalents $357.1M at June 30, 2021; plus $31M net from IPO underwriters' option exercise.","NEK7 NLRP3 degrader program advanced into lead optimization; GSPT1 candidate selection anticipated before year-end.","Appointed Filip Janku, M.D., Ph.D. as CMO; opened research centers in Boston Seaport and Basel.","Anticipates at least one additional program entering lead optimization by end of 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950123-21-010438","json":"https://secwatch.observer/filing/0000950123-21-010438.json","markdown":"https://secwatch.observer/filing/0000950123-21-010438.md","text":"https://secwatch.observer/filing/0000950123-21-010438.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095012321010438/0000950123-21-010438-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095012321010438/d167509d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T13:54:07.760651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}